Company news

Actinogen Medical Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Letter to Shareholders, Notice of AGM & Proxy Form

October 27, 2026

Actinogen receives $10.8m R&D tax incentive rebate from ATO

October 25, 2026

ACW pivotal Alzheimers trial database lock - results mid-Nov

October 20, 2026

ACW pivotal Alzheimers trial database lock - results mid-Nov

October 20, 2026

ACW September 2026 quarterly activity report & Appendix 4C

October 18, 2026

ACW September 2026 quarterly activity report & Appendix 4C

October 18, 2026

Notification of buy-back - ACW

October 11, 2026

AGM date and closing date for director nominations

October 8, 2026

Application for quotation of securities - ACW

September 29, 2026

Actinogen XanaMIA pivotal Alzheimer’s disease trial completes final patient visit, with topline results on track for November

September 23, 2026

Underwriting of unlisted options completed

September 22, 2026

Options underwriting cleansing notice

September 22, 2026

Application for quotation of securities - ACW

September 22, 2026

ACW Alzheimers pivotal trial completes last patient visit

September 22, 2026

Notification of cessation of securities - ACW

September 15, 2026

Application for quotation of securities - ACW

September 15, 2026

Application for quotation of securities - ACW

September 11, 2026

Appendix 3Y-Dr Geoffrey Brooke

September 8, 2026

Application for quotation of securities - ACW

September 8, 2026

ACW CMO international Xanamem presentation

September 8, 2026

Application for quotation of securities - ACW

September 8, 2026

Application for quotation of securities - ACW

September 7, 2026

Response to ASX Price Query

September 4, 2026

Application for quotation of securities - ACW

September 3, 2026

ACW unlisted options fully underwritten

August 31, 2026

Proposed issue of securities - ACW

August 31, 2026

Application for quotation of securities - ACW

August 28, 2026

Appendix 3Y-Dr George Morstyn

August 28, 2026

Appendix 3Y-Dr Geoffrey Brooke

August 28, 2026

Application for quotation of securities - ACW

August 28, 2026

ACW FY2026 results and outlook

August 27, 2026

ACW Appendix 4E and 2026 annual report

August 27, 2026

Appendix 4G

August 27, 2026

Corporate Governance Statement

August 27, 2026

Appendix 3Y - Dr George Morstyn

August 20, 2026

Application for quotation of securities - ACW

August 20, 2026

Appendix 3Y-Malcolm McComas

August 17, 2026

Application for quotation of securities - ACW

August 17, 2026

ACW webinar today, The future of Alzheimers treatment

August 11, 2026

Updated Securities Trading Policy

August 10, 2026

Application for quotation of securities - ACW

August 9, 2026

Notification of cessation of securities - ACW

August 9, 2026

ACW Bioshares presentation, strong cortisol rationale

August 5, 2026

Application for quotation of securities - ACW

August 4, 2026

ACW webinar on the future of Alzheimers treatment

August 4, 2026

June 2026 Quarterly activity report & Appendix 4C

July 29, 2026

Application for quotation of securities - ACW

July 28, 2026

Xanamem depression trial published in British J Psychiatry

July 19, 2026

ACW third positive XanaMIA trial data committee review

June 17, 2026

Actinogen receives positive EMA scientific advice aligned with prior FDA guidance for its Alzheimer’s disease program

May 28, 2026

Older news releases →

Decks

The 5 newest of 87 decks. Every deck is listed under its year.